Radiofrequency and Targeted Pressure Energy for Cellulite Reduction

November 14, 2022 updated by: BTL Industries Ltd.
This study will evaluate the clinical efficacy and safety of radiofrequency heating and targeted pressure energy for reduction in the appearance or cellulite. The study is a prospective multi-center open-label single-arm study. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits - 1, 3 and 6 months after the last therapy visit. All of the study subjects will receive the treatment with the subject device.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This study will evaluate the clinical efficacy and safety of radiofrequency heating and targeted pressure energy for reduction in the appearance or cellulite. The study is a prospective multi-center open-label single-arm study. Subjects will be required to complete four (4) treatment visits and two to three follow-up visits - 1, 3 and 6 months after the last therapy visit. All of the study subjects will receive the treatment with the subject device.

At the baseline visit subject's weight will be recorded, together with hip and thigh circumference. In addition, photographs of the treated area will be taken.

The treatment administration phase will consist of four (4) treatments, delivered in 2-4 weeks. The applicator will be applied over the treatment area.

At the last therapy visit, the subject's weight will be recorded, together with hip and thigh circumference. Photographs of the treated area will be taken. In addition, subjects will receive Subject Satisfaction Questionnaire and Therapy Comfort Questionnaire to fill in.

Safety measures will include documentation of adverse events (AE). Following each treatment administration and at all of the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment.

Study Type

Interventional

Enrollment (Actual)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Coconut Grove, Florida, United States, 33133
        • Dr. Busso Cosmetic Dermatology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Voluntarily signed informed consent form
  • Age ≥ 21 years
  • Subject suffer from Grade 2 or Grade 3 cellulite as per Nürnberger-Muller Scale
  • Subject did not experience weight change exceeding 2.5 kg (5 lb) in the preceding month
  • BMI ≤ 33 kg/m2
  • Women of childbearing potential are required to use birth control measures during the whole duration of the study
  • Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote skin tightening and cellulite reduction during study participation
  • Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation

Exclusion Criteria:

  • Bacterial or viral infection, acute inflammations
  • Impaired immune system
  • Autoimmune disease
  • Diabetes
  • Herpes Simplex
  • Isotretinoin in the past 12 months
  • Scleroderma
  • Radiation therapy
  • Burns in the treatment area
  • Poor healing in the treatment area
  • Metal implants
  • Implantable pacemaker or automatic defibrillator / cardioverter
  • Ablative / non-ablative cosmetic intervention (deep peeling) in the past 3 months
  • Cancer and tumor diseases
  • Active collagen diseases
  • Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis and thrombosis)
  • Pregnancy / nursing or IVF procedure
  • Acute neuralgia and neuropathy
  • Blood disorders, risk of bleeding, bleeding tissues, peptic ulcers
  • Eczema
  • Rosacea
  • Febrile conditions
  • Kidney or liver failure
  • Pronounced edemas, ascites, exudates
  • Sensitivity disorders in the treatment area
  • Varicose veins
  • Local corticosteroid therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BTL-084 Treatment
Radiofrequency and targeted pressure energy devices for the treatment of cellulite
Radiofrequency and targeted pressure energy devices for the treatment of cellulite
Other Names:
  • Emtone

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of cellulite severity change based on photographs before and after the study procedure according to the Cellulite Severity Scale
Time Frame: 6 months
Three independent evaluators will evaluate photographs for a level of cellulite severity by assigning a score according to the Cellulite Severity Scale (CSS) validated by Hexsel et al. After follow-up visits are conducted, evaluators will be given a set of the coded photographs from each subject for an evaluation. The Cellulite Severity Scale evaluates five key morphological features of cellulite; number of depressions, depth of depressions, clinical appearance of evident raised lesions, presence of flaccidity and the grade of cellulite. Each item is graded from 0 to 3, allowing final classification of cellulite as mild, moderate and severe.
6 months
Photography evaluation according to the Global Aesthetic Improvement scale
Time Frame: 6 months
Three independent evaluators will evaluate photographs for a level of appearance change by assigning a score according to the Global Aesthetic Improvement scale, where the lowest possible grade is (-1), worsened state and the highest is (3) very much improved.
6 months
Hip and Thigh Circumference Measure
Time Frame: 6 months
Hip and thigh circumference measurements will be conducted at the baseline visit, after the last treatment and during all follow-up visits.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Therapy Comfort
Time Frame: 6 months
The 10-point scale will be used for evaluating the comfort during the study treatment. Subjects will be evaluating the comfort/discomfort on a scale from 1 ("No discomfort") to 10 ("Unbearable discomfort")
6 months
Subject Satisfaction
Time Frame: 6 months
The 5-point Likert scale Satisfaction questionnaire will be used to evaluate the participant's satisfaction with the therapy outcome. The subjects will be answering questions with possible answers varying from "Strongly disagree" to "Strongly agree"
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 30, 2019

Primary Completion (Actual)

April 8, 2020

Study Completion (Actual)

October 25, 2021

Study Registration Dates

First Submitted

November 14, 2022

First Submitted That Met QC Criteria

November 14, 2022

First Posted (Actual)

November 22, 2022

Study Record Updates

Last Update Posted (Actual)

November 22, 2022

Last Update Submitted That Met QC Criteria

November 14, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cellulitis

Clinical Trials on BTL-084

Subscribe